



IFW

PATENT  
Customer No. 22,852  
Attorney Docket No. 09605.0011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Vittorio DAL PIAZ et al. ) Group Art Unit: 1624  
)  
Application No.: 10/539,821 ) Examiner: Unknown  
)  
§ 371 filing date: December 14, 2005 ) Confirmation No.: 5918  
)  
For: NEW PYRIDAZIN-3(2H)-ONE )  
DERIVATIVES )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE**  
**STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached. A copy of the U.S. patent publication is not enclosed. It is the undersigned's understanding that the cited U.S. copending application is available to the Examiner through the PTO's Image File Wrapper system. Accordingly, a copy of the cited U.S. copending application is not enclosed. See M.P.E.P. § 609.04

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

The following applies to the non-English documents:

1. **DE 2 225 218**. Applicants enclose herewith an English-language machine translation for this document obtained from esp@cenet database.
2. **WO 97/15561**. Applicants enclose herewith an Abstract of the disclosure of this document. Also, U.S. Patent No. 6,025,376 is a member of the patent family of WO 97/15561.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
\_\_\_\_\_  
Carlos M. Tellez  
Reg. No. 48,638

Dated: July 23, 2007

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
		Application Number		10/539,821	
		§ 371 filing date:		December 14, 2005	
		First Named Inventor		Vittorio DAL PIAZ	
		Art Unit		1624	
		Examiner Name		Unassigned	
		Attorney Docket Number		09605.0011	
Sheet	1	of	1		



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-5,679,696	21 OCT 1997	Fenton et al.	
	2	US-6,025,376	15 FEB 2000	Laurent et al.	
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	3	GB 1351569	01 MAY 1974			
	4	DE 2 225 218	20 DEC 1973			yes
	5	WO 01/46184 A1	28 JUN 2001			
	6	WO 99/06404	11 FEB 1999			
	7	WO 97/15561	01 MAY 1997			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	8	Entry No. 3603 for Emorfazone in Merck Index (1994).	
	9	Sato, M. et al., "Studies on Mechanisms of Action of Emorfazone," <i>Arzneim. Forsch./Drug Res.</i> , 32(1)(4):379-382 (1983).	
	10	English-language abstract for WO 97/15561 (01 MAY 1997).	
	11	English-language machine translation of DE 2 225 218 from esp@cenet database (20 DEC 1973).	
	12	U.S. Application No. 10/578,594, filed May 8, 2006.	

Examiner Signature	/Cecilia Jaisle/	Date Considered	08/29/2008
--------------------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./